Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes

Hematology

Volumn 17, Issue 1, 2012, Pages 41-46

  Su, Yongchun ^a   Xu, Hongzhen ^a   Xu, Youhua ^a   Yu, Jie ^a   Xian, Ying ^a   Luo, Qing ^b  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Azacytidine; DNA methylation; Leukemia; Promoter

Indexed keywords

AZACITIDINE; DEATH ASSOCIATED PROTEIN KINASE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEATH ASSOCIATED PROTEIN KINASE GENE; DEMETHYLATION; DNA EXTRACTION; DNA METHYLATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE GENE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; P16 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENES, P16; GENES, REGULATOR; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84863103362     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13221316477624     Document Type: Article

References (31)

1. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001; 293: 1089-1093.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415-428.
3. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 1998; 395: 237-243.
4. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, et al. DAP kinase links the control of apoptosis to metastasis. Nature. 1997; 390: 180-184.
5. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res. 1990; 233: 117-126.
6. Ng MH. Death associated protein kinase: from regulation of apoptosis to tumor suppressive functions and B cell malignancies. Apoptosis. 2002; 7: 261-270.
7. Lin Y, Hupp TR, Stevens C. Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J. 2010; 277: 48-57
8. Qian J, Wang YL, Lin J, Yao DM, Xu WR, Wu CY. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia. Eur J Haematol. 2009; 82: 119-123.
9. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006; 12: 328-331.
10. Hsiao PC, Liu MC, Chen LM, Tsai CY, Wang YT, Chen J, et al. Promoter methylation of p16 and EDNRB gene in leukemia patients in Taiwan. Chin J Physiol. 2008; 51: 27-31.
11. Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, et al. A phase II study of temozolomide therapy for poor-risk patients aged.or 560 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia. 2007; 21: 821-824
12. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neckcancer patients. Cancer Res. 2001; 61: 939-942.
13. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res. 2003; 9: 3635-3640.
14. Mao L. Recent advances in the molecular diagnosis of lung cancer. Oncogene. 2002; 21: 6960-6969.
15. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349: 2042-2054.
16. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7(Suppl 1): 21-29.
17. Gryn J, Zeigler ZR, Shadduck RK, Lister J, Raymond JM, Sbeitan I, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res. 2002; 26: 893-897.
18. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429-2440.
19. Kornblith AB, Herndon JE, 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 2441-2452.
20. Hussain RF, Nouri AM, Oliver RT. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods. 1993; 160: 89-96.
21. Fabiani R, De Bartolomeo A, Rosignoli P, Servili M, Montedoro GF, Morozzi G. Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur J Cancer Prev. 2002; 11: 351-358.
22. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992; 89: 1827-1831.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93: 9821-9826.
24. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005; 11: 3604-3608.
25. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol. 1991; 37: 100-104.
26. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005; 10: 176-182.
27. Kang DW, Choi CH, Park JY, Kang SK, Kim YK. Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells. Neurochem Res. 2008; 33: 551-561.
28. Murakami T, Li X, Gong J, Bhatia U, Traganos F, Darzynkiewicz Z. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. 1995; 55: 3093-3098.
29. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007; 13: 1634-1637.
30. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol. 2000; 183: 145-154.
31. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010; 115: 107-121.